Corporate GovernanceApr 28, 2026, 04:08 PM
LSTA Amends 10-K to Include Corporate Governance & Executive Details
AI Summary
LISATA THERAPEUTICS, INC. filed Amendment No. 1 to its 2026 Form 10-K to include information previously omitted from Part III of the original filing. This amendment provides comprehensive details on the company's directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accounting fees and services. The filing also includes updated certifications and outlines the classified board structure and committee compositions.
Key Highlights
- LISATA THERAPEUTICS, INC. filed Amendment No. 1 to its 2026 Form 10-K.
- The amendment includes previously omitted Part III items: Directors, Executive Officers, Corporate Governance, Executive Compensation, Security Ownership, Related Transactions, and Principal Accounting Fees.
- The Lisata Board consists of six members, classified into three classes.
- Five out of six directors (Dr. Brown, Dr. Azab, Ms. Flowers, Ms. Henson, Mr. Klosk) are independent.
- Key executive officers include David J. Mazzo (CEO) and Kristen K. Buck (CMO).
- Board committees include Audit, Compensation, Nominating & Governance, and Science & Technology.
- An Insider Trading Policy prohibits short sales, margin loans, and hedging, requiring pre-clearance.
Price Impact
More from LSTA